株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

肺動脈高血圧症(PAH)治療薬の世界市場

Pulmonary Arterial Hypertension (PAH) Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 248901
出版日 ページ情報 英文 161 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.15円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
肺動脈高血圧症(PAH)治療薬の世界市場 Pulmonary Arterial Hypertension (PAH) Therapeutics
出版日: 2017年01月01日 ページ情報: 英文 161 Pages
概要

当レポートでは、世界の肺動脈高血圧 (PAH) 市場について調査し、市場の概要と見通し、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 肺動脈高血圧 (PAH) :概要
    • 現在および将来分析
    • クラス別薬剤
    • 肺動脈高血圧 (PAH) の分類
    • WHOによる患者グルーピング
    • 経口治療薬が世界のPAH治療薬を牽引
    • 併用療法がPAHの単一療法より好まれている
    • 小児PAH:アンメットニーズのある潜在的市場
    • 炎症;PAH治療薬の新たな標的
    • 高齢化とPAH
  • 競合シナリオ
    • 主要企業
    • 投与方法別の認可された主要薬剤
    • クラス別ブランド 他
  • PAHパイプライン
  • 製品概要
    • イントロダクション
    • PAHのサブグループ
    • PAHの治療スケジュール
    • PAHの原因と進行
    • PAHの症状
    • PAHの診断
    • 臨床における患者特定
    • PAHの検出
    • PAHの評価と分類 他
  • 製品革新/認可
  • 近年の業界活動
  • 主要参入企業
    • Actelion Pharmaceuticals Ltd
    • Bayer AG
    • Gilead Sciences, Inc.
    • Pfizer, Inc.
    • United Therapeutics Corporation
    • Lung Biotechnology PBC
  • 世界市場見通し

第3章 市場

  • 米国
  • 日本
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • その他

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-7500

This report analyzes the worldwide markets for Pulmonary Arterial Hypertension (PAH) Therapeutics in US$ Million. The Global market is analyzed by the following Drug Class and Brands: Endothelin Receptor Antagonist (Letairis/Volibris, Macitentan, Thelin, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri*, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis, & Orenitram), PDE-5 Inhibitors (Cialis/Adcirca, & Revatio), and Soluble Guanylate Cyclase (sGC) Stimulator (Riociguat). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 31 companies including many key and niche players such as -

Actelion Pharmaceuticals Ltd.
Bayer AG
Gilead Sciences, Inc.
Pfizer, Inc.
United Therapeutics Corporation

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • A. Endothelin Receptor Antagonists (ERAs)
    • B. Prostacyclin and Prostacyclin Analogs
    • C. Phosphodiesterase type 5 (PDE-5) Inhibitors
    • D. Soluble Guanylate Cyclase (sGC) Stimulator

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Pulmonary Arterial Hypertension (PAH) - A Prelude
  • Current & Future Analysis
  • PAH Drugs Market by Class
    • Table 1: Global PAH Market by Drug Class (2016 & 2018): Percentage Share Breakdown of Sales by Drug Class (includes corresponding Graph/Chart)
  • The PAH Classification
  • PH Patient Groupings as per World Health Organization
    • Classification of PAH patients as per New York Heart Association (NYHA)
  • Oral Therapies lead the Global PAH Therapeutics Market
    • Table 2: Global PAH Market by Mode of Drug Usage (2016): Percentage Share Breakdown for Oral, Inhaled, and Injectables (includes corresponding Graph/Chart)
  • Combination Therapy Favored over Monotherapy for PAH
  • Pediatric PAH - A Potential Market with Unmet Need
  • Inflammation: New Target for PAH Therapeutics
  • Aging Population & PAH
    • Table 3: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 4: Global Population by Age-Group: Percentage Change Over the Period 2010-2050 (includes corresponding Graph/Chart)

2. COMPETITIVE SCENARIO

  • Leading Players
    • Table 5: Leading Drugs for PAH (2016): Percentage Share Breakdown of Revenue by Brand (includes corresponding Graph/Chart)
    • Table 6: Leading Players in the Global PAH Therapeutics Market: Percentage Share Breakdown of Revenues by Company (includes corresponding Graph/Chart)
  • Leading Approved Drugs as Per Mode of Administration
  • Major Drug Brands by Class
  • Prostacyclin receptor agonist/ Prostacyclin Analogue
    • Flolan (Epoprostenol)
    • Ventavis (Iloprost)
    • Remodulin (Treprostinil)
    • Orenitram
    • Tyvaso
    • Uptravi (Selexipag)
    • Veletri(r) (Epoprostenol for Injection)
  • Phosphodiesterase 5 inhibitor
    • Revatio
    • Adcirca (Tadalafil)
  • Endothelin receptor antagonists (ERAs)
    • Opsumit
    • Tracleer (Bosentan)
    • Letairis (Ambrisentan)
  • Loss of Market exclusivity Tones Down Growth
    • Patent Expiry of Leading PAH Drugs
  • Opsumit & Uptravi: Game-changers for Actelion
  • Selexipag - Latest Entrant in PAH Therapeutics
  • United Therapeutics - A Major Player
  • Gilead Sciences
  • GlaxoSmithKline
  • Bayer

3. PAH PIPELINE

  • Pulmokine Investigates PDGF Receptor Pathway
  • Reata Pharmaceuticals Completes Phase 3 Study for Bardoxolone methyl
  • Eiger BioPharmaceuticals Commences Phase 2 Trials for Bestatin
  • Insmed Investigates INS 1009
  • LTT Bio-Pharma Focuses on LT-2004
  • Ascendis Investigates TransCon Treprostinil in a Phase I trial
  • Arena Initiates Phase II Trial for Ralinepeg,
  • TheraSilence nanoparticles Found to Reduce Pulmonary Arterial Thickness
  • CXA-10 to Undergo Phase II Study
  • Atu111 Undergoes Preclinical Trial for PH
  • RP5063 - A NCE for PAH
  • SteadyMed to File NDA for Trevyent(r)
  • Pluristem's PLX-PAD
  • Sagene Pharmaceuticals, Inc.
    • Select PAH Therapeutics under Pipeline: 2016

4. PRODUCT OVERVIEW

  • Introduction
  • PAH Subgroups
  • PAH Therapeutics Timeline
    • Timeline for PAH Therapeutics
  • Causes and Development of PAH
  • Symptoms of PAH
  • Diagnosis of PAH
  • Identification of patients on clinical grounds
  • Detection of PAH
  • Evaluation and classification of PAH
  • Overview of Treatments for PAH
  • Treatments for PAH
  • Treatment Pathways in PAH
  • An Insight into PAH Drug Classes
  • Prostacyclin Analogs/Prostanoids
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase type 5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulator
  • PAH Therapies by Class
  • Prostacyclin Analogs/Prostanoids
  • Endothelin (ET-1) Receptor Antagonists
  • Phosphodiesterase-5 (PDE) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Novel Therapies for PAH

5. PRODUCT INNOVATIONS & APPROVALS

  • Nippon Shinyaku Receives Marketing Approval for Uptravi
  • Actelion to Initiate Phase III Study for Pediatric Formulation of Opsumit
  • Actelion Announces USFDA Approval of Uptravi
  • Reata Pharmaceuticals' Bardoxolone Methyl Receives Orphan Drug Designation
  • Actelion Receives Approval for Opsumit from Japan's MHLW
  • Bayer Healthcare Receives Approval for Adempas from Japan's MHLW
  • Silence Therapeutics Develops Gene Toolkit for PAH Research
  • Arena Pharmaceuticals' APD811 Receives Orphan Drug Status for PAH Treatment
  • Bayer's Adempas Approved for Two Rare Types of PAH
  • Actelion's Opsumit Receives Approval from Australia's TGA

6. RECENT INDUSTRY ACTIVITY

  • Arena Pharmaceuticals Initiates Phase 2 Clinical Trial for Ralinepag
  • Gilead Reports Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Pulmonary Arterial Hypertension (PAH)
  • Gilead Sciences Accelerates its PAH Portfolio
  • Mallinckrodt Pharmaceuticals Acquires Ikaria
  • Supernus Pharmaceuticals Receives US$2 million Milestone Payment from United Therapeutics
  • Vectura Group plc Acquires Activaero GmbH
  • Mast Therapeutics Completes Acquisition of Aires Pharmaceuticals

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Actelion Pharmaceuticals Ltd (Switzerland)
  • Bayer AG (Germany)
  • Gilead Sciences, Inc. (US)
  • Pfizer, Inc. (US)
  • United Therapeutics Corporation (US)
  • Lung Biotechnology PBC (US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 7: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 8: World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 9: World 14-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 10: World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2018 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Drugs - Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 12: World 10-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics Market by Drugs - Percentage Breakdown of Dollar Sales for Endothelin Receptor Antagonist (ERA) (Letairis/Volibris, Macitentan, & Tracleer), Prostacyclin and Prostacyclin Analogs (Epoprostenol/Veletri, Flolan, Remodulin, Selexipag, Tyvaso, Ventavis and Orenitram), PDE-5 Inhibitors (Cialis/Adcirca & Revatio (Sildenafil)) and Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat) Markets for Years 2009, 2016 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • High PAH Incidence: Major Market Booster
    • High Costs: Major Challenge for R&D of PAH Therapeutics
    • Aging Population Statistics: Key Opportunity Indicator
    • Table 13: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Prospective Market for Combination Therapies in the US
    • Table 14: PAH Market in the US (2011): Percentage Share Breakdown by Volume for Class of PAH Patients - Class II, Class III, Class I and Class IV (includes corresponding Graph/Chart)
    • Leading Drugs
      • FDA Approved PAH Drugs in the US
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 15: US Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 16: US Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 17: Canadian Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 18: Canadian Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Select Approved and Pipeline Drugs in Japanese PAH market
    • Product Approval
    • LTT Bio-Pharma Co. Ltd.: Key Japan- based Player
  • B. Market Analytics
    • Table 19: Japanese Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 20: Japanese Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analysis
    • Table 21: European Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 22: European Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 23: European 14-Year Perspective for Pulmonary Arterial Hypertension (PAH) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analysis
    • Table 24: French Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: French Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Bayer AG: Key Germany-based Player
  • B. Market Analytics
    • Table 26: German Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: German Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 28: Italian Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Italian Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Silence Therapeutics plc: Key UK-Based Player
  • B. Market Analytics
    • Table 30: UK Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: UK Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 32: Spanish Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: Spanish Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Product Launches/Developments
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 34: Rest of European Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: Rest of European Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Table 36: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 37: Asia-Pacific Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 38: Latin American Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 39: Latin American Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • Market Analysis
    • Table 40: Rest of World Recent Past, Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: Rest of World Historic Review for Pulmonary Arterial Hypertension (PAH) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top